Gemtuzumab ozogamicin, also known as Mylotarg, is a medication used in the treatment of certain types of cancer, specifically acute myeloid leukemia (AML). This drug is a type of targeted therapy known as an antibody-drug conjugate, which works by attaching to specific proteins on cancer cells and delivering a toxic substance directly to the cancer cells, thereby destroying them.

Gemtuzumab is typically used in combination with other chemotherapy medications to treat AML in patients who have not responded to other treatments or who have experienced a relapse. It is administered intravenously by a healthcare provider in a hospital or clinic setting.

As with any medication, Gemtuzumab can cause side effects. Common side effects may include nausea, vomiting, diarrhea, fatigue, fever, and low blood cell counts. More serious side effects may include liver problems, lung problems, and infusion reactions. It is important to discuss any concerns or potential side effects with your healthcare provider.

It is important to follow your healthcare provider’s instructions carefully when taking Gemtuzumab. This may include undergoing regular blood tests to monitor your response to the medication and adjusting your treatment plan as needed.

If you have been prescribed Gemtuzumab for the treatment of AML, it is important to maintain open communication with your healthcare team and to report any new or worsening symptoms promptly. Your healthcare provider will work with you to monitor your progress and adjust your treatment plan as needed to ensure the best possible outcome.